# nChroma Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nchroma-bio

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.nchromabio.com
- Total disclosed funding: $75M
- Latest round: Series I (Dec 11, 2024)
- Investors on record: 19

## About

Founded in 2024 and based in the US, nChroma Bio, formed as a merger between Chroma Medicine and Nvelop Therapeutics, operates as a biotechnology research company that develops genetic medicines using epigenetic editing and in vivo delivery technologies. In December 2024, nChroma Bio raised USD 75 million in venture funding co-led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, and Newpath Partners, with participation from 5 AM Ventures, Data Collective, F-Prime Capital, GV, Janus Henderson Investors, Mubadala Capital, Omega Funds, Sixth Street, Sofinnova Partners, and others. As of 2024, the company is being led by its CEO, Jeff Welsh.

nChroma Bio is a biotechnology company focused on developing in vivo targeted genetic medicine. Its approach addresses limitations in existing genetic therapies by ensuring safe and precise gene delivery. The company's key development candidate, CRMA-1001, is a liver-targeted treatment for chronic hepatitis B and D, utilizing epigenetics to regulate gene expression. The therapy aims to provide a functional cure for these conditions. nChroma Bio is advancing innovative treatments with a focus on durable, targeted gene regulation, with potential applications extending beyond liver-related diseases. 

The company intends to use the December 2024 funding to continue developing its epigenetic editing platform, advance CRMA-1001 for chronic hepatitis B and D coinfection into clinical trials, and support multiple pipeline programs and the development of non-viral delivery vehicles for in vivo applications.

## Funding rounds

- Series I, Dec 11, 2024, $75M — ARCH Venture Partners, Atlas Venture, Menlo Ventures, Sofinnova Partners, Alexandria Venture Investments, 5AM Ventures, Wilson Sonsini, F-Prime Capital, Wellington Management, GV, Janus Henderson Investors, Omega Funds, Casdin Capital, DCVC, Cormorant Asset Management, Mubadala Capital, Sixth Street, Newpath Partners, T Rowe Price Advisory Services

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series I
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series I
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series I
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series I
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series I
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series I
- Wilson Sonsini — Series I
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series I
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series I
- GV (https://capitalatlas.ai/funds/gv) — Series I
- Janus Henderson Investors — Series I
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series I
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series I
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series I
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series I
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series I
- Sixth Street (https://capitalatlas.ai/funds/sixth-street) — Series I
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Series I
- T Rowe Price Advisory Services — Series I